Zymeworks Inc (ZYME) Return on Assets ROA from the third quarter of 2026 to third quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Zymeworks Inc   (NASDAQ: ZYME)


Zymeworks Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Zymeworks Inc 's ROA in the third quarter of 2026?
Zymeworks Inc achieved a return on average assets (ROA) of 7.22 % in its third quarter of 2026, this is above ZYME's average return on assets of -22.93%.
Zymeworks Inc assets over the 12 months ending in its third quarter of 2026 are valued at $600 million

ROA has improved compared to -37.03% in the second quarter of 2026, due to net income growth.

However, within the Healthcare sector 469 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 3566, from total ROA ranking in the second quarter of 2026 at 4102.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Total Assets Change 196.13 % -2.45 % 12.38 % -22.08 % -15.03 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million 43 -150 -103 -81 -63
Return On Assets (TTM) 7.22 % -37.03 % -25.19 % -20.57 % -15.14 %
ZYME's Total Ranking # 3566 # 4102 # 3452 # 3508 # 3737
Total Assets (TTM) in million 1,176 398 478 347 397
Seq. Total Assets Change 195.31 % -16.7 % 38 % -12.77 % -2.72 %
Seq. Net Income Change - - - - -

ZYME's 5 Years Annual ROA >> Back to ZYME Management Effectiveness >> Compare ZYME ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 185
Sector # 470
Overall # 3738

Return On Assets Statistics
High Average Low
35.99 %
-22.93 %
-60.27 %
(Mar 31 2023)   (Sep 30 2022)





Financial Statements
Zymeworks Inc 's Assets $ 1,176 million ZYME's Balance sheet
Zymeworks Inc 's Income $ 174 million Quarterly ZYME's Income Statement
ZYME's Income by Division See ZYME's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change -22.08 % -20.94 % -10.5 % 71.77 % -31.67 %
Total Assets in million 347 445 562 628 366
Y / Y Net Income Change - - - - -
Net Income in million -81 -123 -119 124 -212
Annual Return On Assets -23.41 % -27.59 % -21.1 % 19.79 % -57.9 %

ZYME's 5 Years Annual ROA >> Back to ZYME Management Effectiveness >> Compare ZYME ROA to its Competitors



More Return On Assets Ratios
ZYME's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ZYME's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ZYME's Competitors
Subscribers only: Roa for Zymeworks Inc 's Suppliers
Subscribers only: Return On Assets for ZYME's Customers

You may also want to know
ZYME's Roi ZYME's Inventory Turnover Ratio ZYME's Growth Rates ZYME's Dividend Comparisons
ZYME's Profitability Ratios ZYME's Asset Turnover Ratio ZYME's Dividend Growth
ZYME's Roe ZYME's Valuation Ratios ZYME's Financial Strength Ratios ZYME's Dividend Payout Ratio



Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector ROA
Resmed Inc   18.67 %
Alector Inc   18.37 %
Corcept Therapeutics Inc  18.09 %
Chemed Corporation  17.73 %
Halozyme Therapeutics Inc   17.26 %
Pro dex Inc   16.75 %
Denali Therapeutics Inc   16.42 %
Krystal Biotech Inc   15.48 %
West Pharmaceutical Services Inc   15.47 %
Dexcom Inc   15.47 %
Intuitive Surgical Inc   14.71 %
Vertex Pharmaceuticals Inc  14.16 %
Neurocrine Biosciences Inc   13.69 %
Illumina Inc   13.43 %
Healthcare Services Group Inc   12.79 %
Kiniksa Pharmaceuticals International Plc  12.64 %
Tenet Healthcare Corp  12.39 %
Hca Healthcare Inc   11.73 %
Carlisle Companies Incorporated  11.72 %
Regeneron Pharmaceuticals Inc   11.50 %
Lantheus Holdings Inc   11.43 %
Msa Safety Inc  11.01 %
Encompass Health Corporation  10.99 %
Inspire Medical Systems inc   10.89 %
Transmedics Group Inc   10.67 %
Bristol myers Squibb Company  10.47 %
Lemaitre Vascular Inc   10.28 %
Beone Medicines Ltd   10.23 %
Amgen Inc   10.02 %
Bio rad Laboratories Inc   9.88 %

Date modified: 2026-11-10T10:04:02+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.